Epithelial Sodium Channel Inhibition in Cardiovascular Disease. A Potential Role for Amiloride

American Journal of Hypertension

Volumn 20, Issue 1, 2007, Pages 109-117

  Teiwes, Justin ^a   Toto, Robert D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

amiloride; cardiovascular disease; epithelial sodium channel; Hypertension

Indexed keywords

5 (N ETHYL N ISOPROPYL)AMILORIDE; 5 (N,N DIMETHYL)AMILORIDE; ALDOSTERONE; AMILORIDE; AMILORIDE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZAMIL; CARIPORIDE; DEOXYCORTICOSTERONE ACETATE; DICHLOROBENZAMIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENIPORIDE; HYDROCHLOROTHIAZIDE; IODOAMILORIDE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; PROTEIN INHIBITOR; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN INHIBITOR; SPIRONOLACTONE; TRIAMTERENE; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HORMONE ACTION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISTAL TUBULE; NONHUMAN; OUTCOME ASSESSMENT; POTASSIUM BALANCE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENAL PROTECTION; REVIEW; RISK ASSESSMENT; SODIUM BALANCE; TREATMENT OUTCOME;

ALDOSTERONE; AMILORIDE; ANIMALS; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; EPITHELIAL SODIUM CHANNEL; HUMANS; SODIUM CHANNEL BLOCKERS;

EID: 33845730030     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.05.022     Document Type: Review

References (60)

1. th Edition (2004), Saunders, Philadelphia, PA 438-441
2. Loffing J., Zecevic M., Feraille E., Kaissling B., Asher C., Rossier B.C., Firestone G.L., Pearce D., and Verrey F. Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: possible role of SGK. Am J Physiol Renal Physiol 280 (2001) F675-F682
3. Vuagniaux G., Vallet V., Jaeger N.F., Hummler E., and Rossier B.C. Synergistic activation of ENaC by three membrane-bound channel-activating serine proteases (mCAP1, mCAP2, and MCAP3) and serum- and glucocorticoid-regulated kinase (Sgk1) in Xenopusoocytes. J Gen Physiol 120 (2002) 191-201
4. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
5. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
6. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study). Am J Cardiol 78 (1996) 902-907
7. Chrysostomou A., and Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345 (2001) 925-926
8. Epstein M. Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis for renal dysfunction. J Am Coll Cardiol 39 (2002) 249A
9. Sato A., Hayashi K., Naruse M., and Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 (2003) 64-68
10. Juurlink D.N., Mamdani M.M., Lee D.S., Kopp A., Austin P.C., Laupacis A., and Redelmeier D.A. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
11. Hansson J.H., Schild L., Lu Y., Wilson T.A., Gautschi I., Shimkets R., Nelson-Williams C., Rossier B.C., and Lifton R.P. A de novo missence mutation of the beta subunit of the epithelial Na channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci USA 92 (1995) 11495-1149
12. Jeunemaitre X., Bassilana F., Persu A., Dumont C., Champigny G., Lazdunski M., Corvol P., and Barbry P. Genotype-phenotype analysis of a newly discovered family with Liddle's syndrome. J Hypertension 15 (1997) 1091-1100
13. Cohen A.B. Hyperkalemic effects of triamterene. Ann Intern Med 65 (1966) 521-527
14. Drummond H.A., Gebremedhin D., and Harder D.R. Degenerin/epithelial Na+ channel proteins. Hypertension 44 (2004) 643-648
15. Mano I., and Driscoll M. DEG/ENaC channels: a touchy superfamily that watches salt. Bioassays 21 (1999) 568-578
16. Golestaneh N., Klein C., Valamanesh F., Suarez G., Agarwal M.K., and Mirshahi M. Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun 280 (2001) 1300-1306
17. Mirshahi M., Golestaneh N., Valamanesh F., and Agarwal M.K. Paradoxical effects of mineralocorticoids on the ion gated sodium channel in embryologically diverse cells. Biochem Biophys Res Commun 270 (2000) 811-815
18. Chen W., Valamanesh F., Mirshahi T., Soria J., Tang R., Agarwal M.K., and Mirshahi M. Aldosterone signaling modifies capillary formation by human bone marrow endothelial cells. Vasc Pharmacol 40 (2004) 269-277
19. Oberleithner H., Schneider S.W., Albermann L., Hillebrand U., Ludwig T., Riethmuller C., Shahin V., Schafer C., and Schillers H. Endothelial cell swelling by aldosterone. J Membr Biol 196 (2003) 163-172
20. Oberleithner H., Ludwig T., Riethmuller C., Hillebrand U., Albermann L., Schafer C., Shahin V., and Schillers H. Human endothelium: target for aldosterone. Hypertension 43 (2004) 952-956
21. Campbell S.E., Janicki J.S., Matsubara B.B., and Weber K.T. Myocardial fibrosis in the rat with mineralocorticoid excess. Am J Hypertens 6 (1993) 487-495
22. Mirkovic S., Seymour A.M., Fenning A., Strachan A., Margolin S.B., Taylor S.M., and Brown L. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 135 (2002) 961-968
23. Sepehrdad R., Chander P.N., Oruene A., Rosenfeld L., Levine S., and Stier Jr. C.T. Amiloride reduces stroke and renal injury in stroke-prone hypertensive rats. Am J Hypertens 16 (2003) 312-318
24. Sepehrdad R., Chander P.N., Singh G., and Stier Jr. C.T. Sodium transport antagonism reduces thrombotic microangiopathy in stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol 286 (2004) 1185-1192
25. Kleyman T., and Cragoe E. Amiloride and its analogs as tools in the study of ion transport. J Membrane Biol (1988) 105-121
26. Cragoe Jr. E.J., Woltersdorf Jr. O.W., Bicking J.B., Kwong S.F., and Jones J.H. Pyrazine diuretics. II. N-amidino-3-amino-5-substituted 6-halopyrazinecarboxamides. J Med Chem 10 (1967) 66-75
27. Cragoe E. Structure-activity relationships in the amiloride series. In: Cuthbert A., Fanelli G., and Scriabine A. (Eds). Amiloride and Epithelial Sodium Transport (1978), Urban & Schwarzberg, Baltimore, MD 1-20
28. 6-125I-labeled amiloride derivatives. Anal Biochem 170 (1988) 63-67
29. Spahn H., Reuter K., Mutschler E., Gerok W., and Knauf H. Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol 33 (1987) 493-498
30. Cuthbert A.W., and Fanelli G.M. Effects of some pyrazinecarboxamides on sodium transport in frog skin. Br J Pharmacol 63 (1978) 139-149
31. +exchanger. Eur J Med Chem 38 (2003) 547-554
32. Palandoken H., By K., Hegde M., Harley W.R., Gorin F.A., and Nantz M.H. Amiloride peptide conjugates: prodrugs for sodium-proton exchange inhibition. J Pharmacol Exp Ther 312 (2005) 961-967
33. Canessa C.M., Schild L., Buell G., Thorens B., Gautschi I., Horisberger J.D., and Rossier B.C. Amiloride-sensitive epithelial Na channel is made of three subunits. Nature 367 (1994) 463-467
34. Gomez-Sanchez E.P., and Gomez-Sanchez C.E. Effect of central infusion of benzamil on Dahl S rat hypertension. Am J Physiol 26 (1995) H1044-H1047
35. Nishimura M., Ohtsuka K., Nanbu A., Takahashi H., and Yoshimura M. Benzamil blockade of brain Na+ channels averts Na(+)-induced hypertension in rats. Am J Physiol 274 (1998) R635-R644
36. Huang B.S., and Leenen F.H. Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI. Am J Physiol Heart Circ Physiol 288 (2005) H2491-H2497
37. Amin M.S., Wang H.W., Reza E., Whitman S.C., Tuana B.S., and Leenen F.H. Distribution of epithelial sodium channels and mineralocorticoid receptors in cardiovascular regulatory centers in rat brain. Am J Physiol Regul Integr Comp Physiol 289 (2005) R1787-R1797
38. Kornel L., and Smoszna-Konaszewska B. Aldosterone (ALDO) increases transmembrane influx of Na+ in vascular smooth muscle (VSM) cells through increased synthesis of Na+ channels. Steroids 60 (1995) 114-119
39. Agarwal M. Perspectives in receptor-mediated mineralocorticoid hormone action. Pharmacol Rev 46 (1994) 67-87
40. Schiffrin E.L. The many targets of aldosterone. Hypertension 43 (2004) 938-940
41. Kuhlman D., Ragan C., Ferrebee J., Atchley D., and Loeb R. Toxic effects of deoxycorticosterone esters in dogs. Science 90 (1939) 496-497
42. Brown L., Duce B., Miric G., and Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 10 (1999) S143-S148
43. Stier Jr. C.T., Chander P., Gutstein W.H., Levine S., and Itskovitz H.D. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 4 (1991) 680-687
44. Stier Jr. C.T., Adler L.A., Levine S., and Chander P.N. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 11 (1993) S37-S42
45. Rocha R., and Stier Jr. C.T. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12 (2001) 308-314
46. Rocha R., Chander P.N., Khanna K., Zuckerman A., and Stier Jr. C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 (1998) 451-458
47. Hale S.L., and Kloner R.A. Effect of combined K (ATP) channel activation and Na(+)/H(+) exchange inhibition on infarct size in rabbits. Am J Physiol Heart Circ Physiol 279 (2000) H2673-H2677
48. Avkiran M., and Marber M.S. Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospects. J Am Coll Cardiol 39 (2002) 747-753
49. Kloner R.A., and Rezkalla S.H. Cardiac protection during acute myocardial infarction: where do we stand in 2004?. J Am Coll Cardiol 44 (2004) 276-286
50. Boyce S.W., Bartels C., Bolli R., Chaitman B., Chen J.C., Chi E., Jessel A., Kereiakes D., Knight J., Thulin L., and Theroux P. GUARD During Ischemia Against Necrosis (GUARDIAN) Study Investigators: Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg 126 (2003) 420-427
51. Mentzer Jr. R.M. Effects of Na+/H+ exchange inhibition by cariporide on death and nonfatal myocardial infarction in patients undergoing coronary artery bypass graft surgery: the Expedition Study. Circulation 108 (2003) 2723
52. Zeymer U., Suryapranata H., Monassier J.P., Opolski G., Davies J., Rasmanis G., Linssen G., Tebbe U., Schroder R., Tiemann R., Machnig T., Neuhaus K.L., and ESCAMI Investigators. The Na (+)/H (+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) trial. J Am Coll Cardiol 38 (2001) 1644-1650
53. Gombos E.A., Freis E.D., and Moghadam A. Effects of MK-870 in normal subjects and hypertensive patients. N Engl J Med 275 (1966) 1215-1220
54. Eide I.K., Torjesen P.A., Drolsum A., Babovic A., and Lilledahl N.P. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22 (2004) 2217-2226
55. Saha C., Eckert G.J., Ambrosius W.T., Chun T.Y., Wagner M.A., Zhao Q., and Pratt J.H. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46 (2005) 469-470
56. Farquharson C.A., and Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
57. Farquharson C.A., and Struthers A.D. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart 88 (2002) 475-480
58. Besseghir K., and Rennick B. Renal tubule transport and electrolyte effects of amiloride in the chicken. J Pharmacol Exp Ther 219 (1981) 435-441
59. Chiu T.F., Bullard M.J., Chen J.C., Liaw S.J., and Ng C.J. Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med 30 (1997) 612-615
60. McNay J.L., and Oran E. Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870). Metabolism 19 (1970) 58-70